Researchers have developed a method of administrating methotrexate through polymersomes for improved efficacy when treating ectopic pregnancy.
A new drug delivery system for treating women with ectopic pregnancy has been developed by researchers in the Oregon State University College of Pharmacy.
Ectopic pregnancy is a life-threatening condition where a fertilized egg implants outside the lining of the uterus. About 98% of ectopic pregnancies occur in the fallopian tubes, leading to increased risks of hemorrhage and death.
Approximately 2% of pregnancies in the United States and 1% to 2% worldwide are ectopic, with about 100,000 ectopic pregnancies seen in the United States per year. They are the leading cause of maternal death in the first trimester.
Methotrexate (MTX) has a failure rate of over 10% for treating ectopic pregnancies because of improper accumulation at the implantation site. Researchers developed a drug delivery system to administer MTX through nanoparticles known as polymersomes. This improves the rate of accumulation for MTX and can be given at a comparatively low dose.
Polymersomes are synthetic versions of liposomes. The polymersomes developed by the research team would respond to high concentrations of glutathione in placental cells. This response is achieved at the appropriate time by loading MTX into the polymersomes.
When MTX is delivered, embryonic cells stop dividing. However, this increases the risks of adverse effects such as nausea, vomiting, elevated liver enzymes, diarrhea, lung disease, and kidney damage. A lower dose would reduce adverse events and improve efficacy, according to scientists.
“Developing drugs able to target specific locations in the body remains one of biomedicine’s greatest challenges,” said Olena Taratula of the OSU College of Pharmacy and lead of the study team. “Most of the drugs prescribed today, including MTX, have no means of working only on specific tissues or cells.”
“When drugs affect healthy cells, it can drastically reduce a patient’s quality of life – think of the severe effects of chemotherapy like hair, loss of the lining of the gut, ulcer formation, nausea, etc,” Taratula added.
According to Taratula, the study of MTX delivered by polymersomes in mice induced end of pregnancy and led to healthy offspring being born. Taratula has recently received a grant to develop a magnetic nanoparticle platformthat may be more effective than the light-sensitive nanoparticles currently used because of having deeper tissue penetration.
Reference
New drug delivery system shows promise in treatment of life-threatening pregnancy condition. Oregon State University. July 24, 2023. Accessed July 25, 2023. https://www.eurekalert.org/news-releases/996593
Buprenorphine use in pregnancy linked to decreased fetal breathing movements
May 18th 2024According to a poster presented at ACOG 2024, use of the synthetic opioid buprenorphine depressed fetal breathing in biophysical profile assessments, but had no significant impact on other factors like amniotic fluid index or fetal tone.
Read More
S4E3: Myfembree for moderate-to-severe endometriosis pain: Potential for adolescents
March 2nd 2022In this episode of Pap Talk, Contemporary OB/GYN® Associate Editor Lindsey Carr sat down with Jessica Shim, MD, an attending at in the Division of Gynecology, Department of Surgery, Boston Children’s Hospital; Harvard Medical School Boston, Massachusetts, to discuss Myfembree (relugolix, estradiol, and norethindrone acetate tablets; Myovant Sciences, Pfizer) and its possible approval in May 2022.
Listen
Identifying gaps in syphilis treatment and prenatal care among pregnant individuals
May 17th 2024Preventing congenital syphilis comes down to quick diagnosis and treatment of the infection in pregnancy, and the number of missed opportunities to do so in the United States continues to grow.
Read More
S4E1: New RNA platform can predict pregnancy complications
February 11th 2022In this episode of Pap Talk, Contemporary OB/GYN® sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.
Listen
Impact of antiepileptic medications and sex hormones on maternal and child outcomes in epilepsy
May 16th 2024Paula Emanuela Voinescu, MD, PhD, director of the Women's Epilepsy Program at Brigham and Women's Hospital, talked about the influence of sex hormones on maternal outcomes in pregnant women with epilepsy treated with antiseizure medication.
Read More
Prenatal cannabis and nicotine use linked to adverse pregnancy outcomes
May 14th 2024A recent study highlights the heightened risks of maternal and neonatal morbidity and mortality associated with combined cannabis and nicotine use during pregnancy, urging further investigation into their impact on short- and long-term outcomes.
Read More